No definition available.
Endpoint definition
↥
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
520210 |
1. Apply sex-specific ruleNone |
520210 |
2. Check conditionsNone |
520210 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
2 out of 7 registries used, show all original rules. |
426 |
4. Check minimum number of eventsNone |
426 |
5. Include endpointsNone |
426 |
6. Filter based on genotype QC (FinnGen only) |
426 |
Control definitions (FinnGen only)
- Control exclude
- H7_OCUMUSCLE
Extra metadata
- Level in the ICD hierarchy
- 4
- First used in FinnGen datafreeze
- DF2
Similar endpoints
↥List of similar endpoints to
Other specified and unspecified strabismus
based on the number of shared cases.
Similar with more cases:
- Other strabismus
- Strabismus
- Disorders of ocular muscles, binocular movement, accommodation and refraction
- Diseases of the eye and adnexa
- Any event in hilmo or specialist outpatient
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 4547 | 2406 | 2136 |
| Only index persons | 3496 | 1882 | 1614 |
| Unadjusted period prevalence (%) | |||
| Whole population | 0.06 | 0.07 | 0.06 |
| Only index persons | 0.07 | 0.07 | 0.06 |
| Median age at first event (years) | |||
| Whole population | 9.45 | 11.12 | 7.46 |
| Only index persons | 16.21 | 20.13 | 11.64 |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 426 | 273 | 153 |
| Unadjusted period prevalence (%) | 0.08 | 0.09 | 0.07 |
| Median age at first event (years) | 41.69 | 41.10 | 42.76 |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
-FinnGen-
Cumulative Incidence Function
No data
CodeWAS (R11)
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 377
- Matched controls
- 3769
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
H50.9
ICD-10 Finland
Strabismus, unspecified
821.3
192.9
174
*
H50.8
ICD-10 Finland
Other specified strabismus
+∞
173.8
153
*
H50.0
ICD-10 Finland
Convergent concomitant strabismus
+∞
62.2
58
*
37309
ICD-8 Finland
Strabismus, Unspecified
+∞
56.7
53
*
H50.2
ICD-10 Finland
Vertical strabismus
+∞
56.7
53
*
CEC10
NOMESCO Finland
Recession and resection of extraocular muscle
+∞
49.0
46
*
H53.2
ICD-10 Finland
Diplopia
30.6
47.8
64
25
H50.31
ICD-10 Finland
Intermittent exotropia
+∞
42.5
40
*
CEC00
NOMESCO Finland
Recession of extraocular muscle
+∞
41.4
39
*
H50.1
ICD-10 Finland
Divergent concomitant strabismus
+∞
37.1
35
*
XCW99
NOMESCO Finland
Other investigative procedure of eye
7.3
34.4
90
156
H06.2*E05.9
ICD-10 Finland
Dysthyroid exophthalmos
76.8
31.5
35
5
H50.52
ICD-10 Finland
Exophoria
278.6
26.0
26
*
E05.0
ICD-10 Finland
Thyrotoxicosis with diffuse goitre
15.6
25.5
42
30
H50.30
ICD-10 Finland
Intermittent esotropy
+∞
25.3
24
*
Z01.0
ICD-10 Finland
Examination of eyes and vision
4.1
24.5
112
354
37300
ICD-8 Finland
Strabismus, Concomitans convergens
+∞
21.0
20
*
H062, E050
ICD-10 Finland
NA
+∞
18.9
18
*
CEW99
NOMESCO Finland
Other operation on extraocular muscle
+∞
18.9
18
*
CA1BG
NOMESCO Finland
Eye and orbita MRI examination with high intensity magnet
52.6
17.2
20
*
H50.51
ICD-10 Finland
Esophoria
+∞
16.8
16
*
H49.2
ICD-10 Finland
Sixth [abducent] nerve palsy
+∞
15.7
15
*
CEC60
NOMESCO Finland
Transposition of extraocular muscle with adjustable suture
+∞
15.7
15
*
H50.6
ICD-10 Finland
Mechanical strabismus
+∞
14.7
14
*
H49.1
ICD-10 Finland
Fourth [trochlear] nerve palsy
+∞
14.7
14
*
AA1DG
NOMESCO Finland
Very extensive MRI examination of brain with high intensity magnet
9.0
14.3
30
36
H53.1
ICD-10 Finland
Subjective visual disturbances
5.3
13.6
42
87
E05.9
ICD-10 Finland
Thyrotoxicosis, unspecified
9.3
13.2
27
31
H06.2
ICD-10 Finland
Dysthyroid exophthalmos
72.3
12.7
14
*
H03BB01
ATC
carbimazole; oral
6.6
12.6
32
52
CEC90
NOMESCO Finland
Total transposition of extraocular muscle or muscles
+∞
11.5
11
*
CA1CG
NOMESCO Finland
Eye and orbita extensive MRI examination with high intensity magnet
44.7
11.0
13
*
H53.0
ICD-10 Finland
Amblyopia ex anopsia
19.5
10.3
15
8
S01XA20
ATC
artificial tears and other indifferent preparations; ophthalmic
2.2
10.3
142
825
A12AX
ATC
Calcium, combinations with vitamin D and/or other drugs
2.2
9.9
119
646
XCK00
NOMESCO Finland
Perimetry
4.2
9.5
36
93
H51.1
ICD-10 Finland
Convergence insufficiency and excess
+∞
9.4
9
*
CAC30
NOMESCO Finland
Decompression of orbit to sinuses
+∞
9.4
9
*
37301
ICD-8 Finland
Strabismus, Concomitans divergens
+∞
9.4
9
*
H03AA01
ATC
levothyroxine sodium; systemic
2.3
8.8
92
466
H55
ICD-10 Finland
Nystagmus and other irregular eye movements
51.2
8.7
10
*
H52.0
ICD-10 Finland
Hypermetropia
16.8
8.6
13
8
AA1CG
NOMESCO Finland
Extensive MRI examination of brain with high intensity magnet
3.2
8.4
43
144
H52.1
ICD-10 Finland
Myopia
7.2
7.9
18
26
111
Kela drug reimbursment
Epilepsy and comparable convulsive disorders
4.2
7.9
29
74
WX408
NOMESCO Finland
General anesthesy, balanced
2.0
7.7
113
659
ZXA00
NOMESCO Finland
Right side
2.1
7.6
97
534
H52.3
ICD-10 Finland
Anisometropia and aniseikonia
81.6
7.4
8
*
3503
FHL
Single muscle retroposition
+∞
7.3
7
*
CAC44
NOMESCO Finland
Combined decompression of orbit
+∞
7.3
7
*
BAA60
NOMESCO Finland
Total thyroidectomy
5.2
7.2
21
42
ZX012
NOMESCO Finland
Radiotherapy with large shaped fields - isocentric therapy
4.2
7.1
26
66
ZX090
NOMESCO Finland
Other technic of radiotherapy
7.8
7.0
15
20
ZX120
NOMESCO Finland
Intravenous
2.8
6.9
43
164
H52.2
ICD-10 Finland
Astigmatism
23.0
6.7
9
*
N03AX14
ATC
levetiracetam; systemic
5.9
6.5
17
30
CA1CM
NOMESCO Finland
Eye and orbita extensive MRI examination with 3 Tesla magnet
71.0
6.4
7
*
F95
ICPC
Strabismus
71.0
6.4
7
*
3780A
ICD-9 Finland
Strabismus and other disorders of binocular eye movements, Convergent concomitant strabismus[STRABISMUS CONCOMITANS CONVERGENS]
+∞
6.3
6
*
37303
ICD-8 Finland
Strabismus, Heterophoria (exophoria, esophroria, hypophoria)
+∞
6.3
6
*
3780B
ICD-9 Finland
Strabismus and other disorders of binocular eye movements, Convergent concomitant strabismus[STRABISMUS CONVERGENS ALTERNANS]
+∞
6.3
6
*
3504
FHL
Retroposition of two muscles
+∞
6.3
6
*
CEC30
NOMESCO Finland
Resection of extraocular muscle
+∞
6.3
6
*
CE2W4
NOMESCO Finland
Eye movement mapping
+∞
6.3
6
*
R5110
NOMESCO Finland
Evaluation of the need for aids, the testing, fitting and choice of the aid, instruction in use and delivery of it
2.5
6.3
47
201
H02.4
ICD-10 Finland
Ptosis of eyelid
5.5
6.2
17
32
H02AB06
ATC
prednisolone; systemic
1.8
6.2
157
1091
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
44
90
5.34
20.88
3.5
1.9
6.3
6.4
iu/l
0.01
27
34
215
1547
1.79
7.92
7.8
6.3
1.2
1.2
mmol/l
0.36
186
1322
172
1171
1.79
7.55
2.1
1.8
92.2
96.3
pmol/l
0.44
100
580
136
877
1.81
7.08
2.6
2.1
206.8
185.0
u/l
0.13
123
829
195
1405
1.72
6.83
7.3
6.1
1.2
1.2
mmol/l
0.13
188
1283
13
26
5.13
6.26
1.2
1.0
—
—
—
0
0
44
210
2.22
5.33
4.0
3.3
4.2
4.6
pmol/l
2.39
44
188
172
1278
1.58
4.89
6.9
4.6
35.7
36.4
g/l
0.86
167
1203
315
2694
1.65
4.85
5.3
3.9
14.8
14.6
pmol/l
0.55
307
2476
181
1377
1.55
4.56
3.1
2.3
72.3
75.5
nmol/l
0.85
167
1256
14
39
3.68
4.52
1.1
1.1
—
—
—
0
0
155
1141
1.56
4.51
3.9
3.1
—
—
—
0
0
14
40
3.58
4.37
1.1
1.1
—
—
—
0
0
244
2006
1.51
4.13
12.1
9.3
3.9
3.9
e9/l
0.19
221
1759
52
299
1.84
3.81
8.8
7.4
0.9
1.0
mmol/l
0.05
43
237
125
909
1.53
3.73
3.4
3.1
0.3
0.4
e6/l
0.36
99
674
30
143
2.18
3.69
8.2
10.2
24.4
24.2
mmol/l
0.09
30
135
228
1880
1.46
3.60
5.8
4.7
6.3
6.5
mmol/l
0.82
219
1727
20
81
2.54
3.51
1.9
2.5
24.8
6.7
e6/l
0.49
13
64
20
81
2.54
3.51
1.9
2.6
9708.6
360.3
e6/l
0.51
14
67
12
36
3.40
3.50
1.2
1.1
—
—
—
0
0
380
3506
1.78
3.40
16.8
11.8
23.6
21.7
mg/l
0.46
299
2687
290
2522
1.47
3.35
4.5
3.9
10.7
10.4
mm/h
0.13
280
2326
109
786
1.52
3.35
2.9
2.3
2.8
3.1
mg/l
0.67
93
675
56
343
1.73
3.33
23.6
18.4
1.3
1.3
inr
—
6
47
202
1647
1.43
3.29
6.4
6.1
12.4
11.8
umol/l
0.16
190
1558
372
3428
1.67
3.14
18.3
13.3
139.8
139.7
mmol/l
0.84
366
3340
373
3441
1.68
3.12
18.5
13.4
3.9
4.0
mmol/l
0.82
365
3345
138
1059
1.45
3.08
4.3
2.9
2.3
2.4
mmol/l
0.87
125
938
8
16
5.07
3.06
2.6
1.4
—
—
—
0
0
286
2505
1.43
3.00
8.7
6.7
81.9
80.7
u/l
0.13
276
2351
86
603
1.53
2.98
1.4
1.6
428.8
12885057.8
pmol/l
0.50
79
520
35
193
1.89
2.94
1.5
1.6
31.0
23.1
iu/l
0.49
29
158
193
1588
1.39
2.87
3.6
2.6
130.8
99.7
ug/l
0.68
177
1479
128
985
1.43
2.78
2.6
2.4
49.9
56.3
u/l
1.58
119
911
(3020427) Coagulation factor X inhibitor [Units/volume] in Platelet poor plasma by Coagulation assay
17
72
2.42
2.76
4.5
4.5
0.4
0.4
u/ml
—
8
39
40
237
1.76
2.69
1.4
2.8
68.6
70.4
ml/min/173m2
0.10
11
100
(3016894) Varicella zoster virus DNA [Presence] in Cerebral spinal fluid by NAA with probe detection
8
19
4.27
2.69
1.9
1.2
—
—
—
0
0
9
24
3.81
2.68
2.0
1.9
—
—
—
0
0
7
15
4.73
2.60
1.9
1.1
—
—
—
0
0
74
520
1.51
2.54
3.8
2.9
4.1
2.4
e6/l
0.52
48
287
7
18
3.93
2.26
4.6
3.1
28.6
28.9
umol/l
—
7
18
137
1108
1.35
2.14
3.1
3.2
47.7
30.9
u/l
0.74
131
1054
100
769
1.39
2.13
2.7
3.4
1528.1
931.9
ng/l
0.35
87
648
344
3187
1.41
2.10
6.3
4.6
1.9
2.2
mu/l
0.50
338
2959
111
872
1.37
2.08
4.3
3.5
0.0
0.0
estimate
0.80
46
329
16
76
2.15
2.05
1.4
1.5
—
—
—
0
0
194
1658
1.31
2.05
3.7
3.3
0.0
0.0
estimate
0.00
44
330
6
15
4.04
2.04
1.2
1.5
—
—
—
0
0
6
15
4.04
2.04
1.2
1.5
—
—
—
0
0
39
250
1.62
2.01
7.6
9.5
24.7
24.7
mmol/l
0.02
39
250
67
485
1.45
2.00
1.7
1.6
1222.6
1211.4
nmol/l
0.03
55
369
178
1516
1.30
1.89
4.3
3.8
—
—
—
0
0
328
3037
1.35
1.83
21.5
14.8
13.6
13.5
%
0.26
323
2989
9
36
2.53
1.75
1.2
1.1
—
—
—
0
0
72
542
1.40
1.74
2.9
2.8
1.5
0.9
e6/l
0.56
45
304
104
832
1.33
1.71
4.0
4.0
19.8
10.4
mg/mmol
0.38
68
527
88
688
1.35
1.69
1.6
1.5
19.5
21.5
nmol/l
0.66
81
585
32
205
1.61
1.68
2.1
1.5
—
—
—
0
0
6
19
3.19
1.66
1.0
1.2
1.8
1.6
mmol/l
—
6
19
194
1691
1.27
1.66
3.7
3.4
0.0
0.0
estimate
0.50
46
321
319
2962
1.31
1.60
5.8
5.1
39.0
38.9
mmol/mol
0.02
309
2783
192
1677
1.26
1.60
4.9
4.6
0.0
0.0
estimate
0.50
45
336
329
3074
1.31
1.53
15.4
10.8
85.3
86.6
ml/min/173m2
0.45
262
2459
92
741
1.31
1.44
1.9
2.1
2.1
1.4
mg/l
0.23
64
557
5
16
3.15
1.44
2.6
1.3
—
—
—
0
0
54
402
1.39
1.41
3.0
2.2
2.4
2.4
g/l
0.08
49
369
93
755
1.30
1.38
3.0
2.2
—
—
—
0
0
68
528
1.34
1.37
3.2
2.7
2.4
2.4
mmol/l
0.65
60
460
131
1112
1.26
1.36
3.6
3.6
23.3
35.1
ng/l
1.06
82
702
70
548
1.33
1.34
3.5
3.6
44.9
313.4
ng/l
3.65
48
391
25
162
1.58
1.29
1.8
1.6
—
—
—
0
0
12
62
1.96
1.29
1.1
1.1
—
—
—
0
0
12
62
1.96
1.29
1.1
1.1
—
—
—
0
0
26
172
1.54
1.24
4.7
2.3
1.4
0.1
e6/l
0.51
26
163
(40770918) von Willebrand factor (vWf).activity actual/normal in Platelet poor plasma by Immunoassay
5
19
2.65
1.22
1.4
2.0
111.4
115.7
%
—
5
19
5
19
2.65
1.22
3.0
2.4
—
—
—
0
0
88
731
1.26
1.09
3.6
3.3
1.0
1.0
kg/l
0.42
14
94
7
32
2.21
1.08
1.0
1.0
—
—
—
0
0
5
22
2.29
1.03
1.4
3.0
107.8
92.9
%
—
5
22
347
3315
1.25
1.02
19.5
12.8
39.1
40.3
%
1.59
269
2616
5
23
2.19
0.98
4.2
3.4
—
—
—
0
0
249
2312
1.19
0.96
3.1
3.0
42.3
41.6
u/l
0.06
236
2196
73
603
1.25
0.96
1.3
1.3
44.9
33.3
iu/ml
0.18
17
187
143
1270
1.19
0.92
4.1
3.4
—
—
—
0
0
23
160
1.46
0.91
1.5
1.3
—
—
—
0
0
70
581
1.25
0.89
1.2
1.3
31.6
9.2
u/ml
0.39
24
230
106
920
1.20
0.88
1.3
1.4
0.9
2.2
u/ml
2.02
33
230
46
364
1.30
0.86
2.7
3.1
6.8
7.1
umol/l
0.11
39
313
38
293
1.33
0.85
3.4
3.1
—
—
—
0
0
6
31
1.95
0.84
1.5
1.3
—
—
—
0
0
42
329
1.31
0.84
6.1
6.7
—
—
—
0
0
377
3657
1.27
0.82
12.3
9.3
27.2
26.1
u/l
0.29
369
3543
42
331
1.30
0.81
5.2
5.7
6.3
5.7
kpa
1.51
42
323
20
139
1.46
0.80
2.4
1.7
—
—
—
0
0
0
26
0.00
0.78
0.0
1.6
—
—
—
0
0
16
108
1.50
0.74
1.5
1.3
—
—
—
0
0
41
327
1.28
0.74
5.3
5.8
2.7
1.6
mmol/l
0.84
35
253
15
100
1.52
0.74
1.1
1.2
0.8
2.2
u/ml
—
7
48
13
84
1.56
0.72
1.1
1.4
—
—
—
0
0
39
311
1.28
0.71
2.2
2.2
32.0
31.3
u/l
0.02
34
261
7
118
0.59
0.69
1.1
1.4
—
—
—
0
0
7
118
0.59
0.69
1.1
1.4
—
—
—
0
0
7
118
0.59
0.69
1.1
1.4
—
—
—
0
0
328
3156
1.17
0.68
4.4
4.0
5.9
5.8
mmol/l
0.35
313
2918
323
3105
1.17
0.67
3.6
3.6
1.3
1.3
mmol/l
0.60
311
2884
5
28
1.79
0.66
3.4
2.0
—
—
—
0
0
50
597
0.82
0.66
2.3
2.3
—
—
—
0
0
88
776
1.17
0.62
2.4
2.7
328.6
5506.0
umol/l
2.92
82
680
0
21
0.00
0.60
0.0
5.6
—
37.6
—
0
5
17
230
0.73
0.59
1.4
1.5
—
—
—
0
0
9
60
1.51
0.54
1.1
1.3
—
—
—
0
0
12
83
1.46
0.52
1.1
1.5
411.6
211.8
u/ml
—
7
45
9
64
1.41
0.51
1.4
1.5
15.9
20.2
u/l
—
9
53
9
65
1.39
0.51
1.2
1.2
15.9
3.2
ug/l
—
9
57
47
548
0.84
0.50
2.1
2.1
—
—
—
0
0
18
233
0.76
0.48
1.4
1.3
—
—
—
0
0
29
352
0.81
0.47
1.4
1.6
—
—
—
0
0
8
118
0.67
0.46
1.1
1.4
—
—
—
0
0
9
129
0.69
0.44
1.1
1.5
—
—
—
0
0
14
104
1.36
0.43
1.8
2.1
—
—
—
0
0
12
87
1.39
0.42
1.1
1.2
—
—
—
0
0
13
96
1.37
0.42
2.1
2.3
—
—
—
0
0
8
58
1.39
0.41
1.0
1.1
—
—
—
0
0
11
79
1.40
0.41
1.6
3.7
3.9
3.8
mmol/l
0.09
11
70
11
79
1.40
0.41
2.3
2.7
2.7
0.8
g/l
0.31
11
71
54
476
1.15
0.41
1.9
1.8
—
—
—
0
0
332
3236
1.12
0.40
4.0
4.0
4.6
4.7
mmol/l
0.74
320
3028
5
34
1.48
0.40
1.0
1.1
—
—
—
0
0
12
88
1.37
0.40
1.7
2.6
—
—
—
0
0
337
3288
1.12
0.40
4.7
4.4
2.7
2.8
mmol/l
0.85
326
3048
0
18
0.00
0.40
0.0
1.7
—
—
—
0
0
5
35
1.43
0.39
1.4
3.6
—
—
—
0
0
5
79
0.63
0.36
1.2
1.7
—
—
—
0
0
12
155
0.77
0.34
1.7
1.6
—
—
—
0
0
6
47
1.28
0.32
3.3
2.8
5.3
93.4
u/ml
—
6
41
11
83
1.33
0.32
1.4
1.4
—
—
—
0
0
24
202
1.20
0.32
7.5
7.4
24.9
23.8
mmol/l
0.67
24
188
10
76
1.32
0.28
2.0
1.7
—
—
—
0
0
8
67
1.20
0.26
2.0
1.4
—
—
—
0
0
22
188
1.18
0.26
3.2
2.3
11392.3
3411.3
u/l
—
6
69
9
73
1.24
0.25
1.1
2.1
—
—
—
0
0
14
114
1.24
0.25
2.1
2.0
—
—
—
0
0
9
76
1.19
0.24
1.6
2.4
38.4
39.2
g/l
—
9
66
13
106
1.23
0.23
1.8
1.8
—
—
—
0
0
5
40
1.25
0.22
2.0
1.5
—
—
—
0
0
5
40
1.25
0.22
1.4
1.3
—
—
—
0
0
5
40
1.25
0.22
2.0
1.5
—
—
—
0
0
5
40
1.25
0.22
2.0
1.4
—
—
—
0
0
11
135
0.81
0.22
1.6
1.6
—
—
—
0
0
5
41
1.22
0.22
2.0
1.5
—
—
—
0
0
5
41
1.22
0.22
2.0
1.5
—
—
—
0
0
5
41
1.22
0.22
2.0
1.5
—
—
—
0
0
25
283
0.88
0.22
1.3
1.3
135.7
158.8
iu/ml
—
8
121
61
567
1.09
0.21
4.8
4.2
22.1
20.9
%
0.23
26
236
0
11
0.00
0.21
0.0
3.4
—
—
—
0
0
0
11
0.00
0.21
0.0
1.4
—
—
—
0
0
0
11
0.00
0.21
0.0
1.2
—
—
—
0
0
0
11
0.00
0.21
0.0
3.4
—
—
—
0
0
0
10
0.00
0.21
0.0
1.4
—
—
—
0
0
0
10
0.00
0.21
0.0
1.1
—
—
—
0
0
0
12
0.00
0.21
0.0
2.1
—
—
—
0
0
0
13
0.00
0.21
0.0
2.0
—
—
—
0
0
13
108
1.21
0.20
1.2
1.1
—
—
—
0
0
6
49
1.23
0.20
1.2
1.3
7.5
7.6
mmol/l
—
6
28
13
109
1.20
0.19
1.2
1.1
—
—
—
0
0
36
330
1.10
0.17
1.8
1.7
—
—
—
0
0
326
3217
1.06
0.16
4.0
4.0
1.4
1.5
mmol/l
1.40
315
2989
8
71
1.13
0.16
1.4
1.3
—
43.9
—
0
7
8
73
1.10
0.16
1.1
1.2
—
—
—
0
0
8
73
1.10
0.16
1.3
1.2
—
—
—
0
0
13
112
1.17
0.14
1.2
1.2
—
—
—
0
0
8
96
0.83
0.14
2.0
1.7
—
—
—
0
0
87
904
0.95
0.13
1.7
1.7
—
—
—
0
0
15
133
1.13
0.12
1.4
1.3
171.2
285.1
miu/ml
—
8
69
21
229
0.91
0.11
1.1
1.0
—
—
—
0
0
28
261
1.08
0.10
7.3
4.5
0.7
1.5
mmol/l
0.54
22
185
5
44
1.14
0.10
1.0
1.3
—
—
—
0
0
30
281
1.07
0.10
2.0
1.8
—
—
—
0
0
7
84
0.83
0.07
1.4
1.6
—
—
—
0
0
9
86
1.05
0.07
1.1
1.3
—
—
—
0
0
35
335
1.05
0.06
1.8
1.7
—
—
—
0
0
13
120
1.09
0.05
1.2
1.3
—
—
—
0
0
28
270
1.04
0.03
4.1
4.4
5.4
6.9
ug/l
0.18
21
231
43
420
1.03
0.02
3.2
2.8
0.6
0.7
ug/l
0.34
26
253
85
860
0.99
0.02
1.6
1.6
1.3
1.4
mmol/l
0.84
77
740
14
133
1.05
0.01
2.5
1.4
1.3
1.2
g/l
0.88
14
127
12
116
1.04
0.00
1.7
1.4
—
—
—
0
0
12
124
0.97
0.00
1.8
1.5
—
—
—
0
0
11
108
1.02
0.00
1.7
1.6
—
—
—
0
0
36
358
1.01
0.00
2.0
1.9
—
—
—
0
0
62
622
1.00
0.00
1.6
1.5
—
—
—
0
0
262
2617
1.00
0.00
3.5
3.4
—
—
—
0
0
6
61
0.98
0.00
5.5
3.3
20.0
30.3
u/ml
—
6
61
0
5
0.00
0.00
0.0
1.6
—
—
—
0
0
5
55
0.91
0.00
1.0
1.1
—
—
—
0
0
8
84
0.95
0.00
1.6
1.5
—
—
—
0
0
7
69
1.01
0.00
1.0
1.1
—
—
—
0
0
0
6
0.00
0.00
0.0
1.0
—
—
—
0
0
6
69
0.87
0.00
1.0
1.3
—
—
—
0
0
0
5
0.00
0.00
0.0
1.2
—
—
—
0
0
0
5
0.00
0.00
0.0
1.2
—
—
—
0
0
0
7
0.00
0.00
0.0
1.3
—
—
—
0
0
0
6
0.00
0.00
0.0
1.2
—
—
—
0
0
0
5
0.00
0.00
0.0
1.4
—
—
—
0
0
0
9
0.00
0.00
0.0
1.2
—
—
—
0
0
7
72
0.97
0.00
2.3
1.7
191.7
237.7
pmol/l
—
7
67
0
6
0.00
0.00
0.0
1.3
—
—
—
0
0
7
75
0.93
0.00
1.6
1.3
—
1.0
—
0
5
5
52
0.96
0.00
1.0
1.4
—
—
—
0
0
6
59
1.02
0.00
1.2
1.6
—
—
—
0
0
0
9
0.00
0.00
0.0
1.2
—
—
—
0
0
0
7
0.00
0.00
0.0
3.7
—
—
—
0
0
0
6
0.00
0.00
0.0
3.0
—
—
—
0
0
0
6
0.00
0.00
0.0
2.8
—
1.5
—
0
6
0
6
0.00
0.00
0.0
1.2
—
—
—
0
0
Mortality – FinRegistry
↥Association
Association between endpoint H7_STRABNAS and mortality.
Females
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| H7_STRABNAS | 1.175 [0.87, 1.58] | 0.284 |
| Birth year | 0.994 [0.99, 1.0] | 0.171 |
During the follow-up period (1.1.1998 — 31.12.2019), 80 out of 1777 females with H7_STRABNAS died.
Males
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| H7_STRABNAS | 1.232 [0.89, 1.7] | 0.202 |
| Birth year | 0.987 [0.98, 1.0] | 0.016 |
During the follow-up period (1.1.1998 — 31.12.2019), 75 out of 1539 males with H7_STRABNAS died.
Mortality risk
Mortality risk for people of age
years, who have H7_STRABNAS.| N-year risk | Females | Males |
|---|---|---|
| 1 | 0.091% | 0.215% |
| 5 | 0.655% | 1.266% |
| 10 | 1.807% | 3.642% |
| 15 | 3.292% | 7.24% |
| 20 | 5.626% | 11.799% |
Relationships between endpoints
↥Index endpoint: H7_STRABNAS – Other specified and unspecified strabismus
GWS hits: 1
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data